Related references
Note: Only part of the references are listed.Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer
Kari B. Wisinski et al.
CLINICAL CANCER RESEARCH (2016)
A Phase 1 Study of Cetuximab and Lapatinib in Patients With Advanced Solid Tumor Malignancies
John F. Deeken et al.
CANCER (2015)
Predictors of early treatment discontinuation in patients enrolled on Phase I oncology trials
David M. Hyman et al.
ONCOTARGET (2015)
Lapatinib induces p27Kip1-dependent G1 arrest through both transcriptional and post-translational mechanisms
Lin Tang et al.
CELL CYCLE (2013)
Lapatinib-induced NF-kappaB activation sensitizes triple-negative breast cancer cells to proteasome inhibitors
Yun-Ju Chen et al.
BREAST CANCER RESEARCH (2013)
Low molecular weight cyclin E is associated with p27-resistant, high-grade, high-stage and invasive bladder cancer
Said Akli et al.
CELL CYCLE (2012)
Temporal Profiling of Lapatinib-suppressed Phosphorylation Signals in EGFR/HER2 Pathways
Koshi Imami et al.
MOLECULAR & CELLULAR PROTEOMICS (2012)
Lapatinib for Advanced or Metastatic Breast Cancer
Frans L. Opdam et al.
ONCOLOGIST (2012)
One-Step Preservation of Phosphoproteins and Tissue Morphology at Room Temperature for Diagnostic and Research Specimens
Claudius Mueller et al.
PLOS ONE (2011)
Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor
A. Z. Dudek et al.
BRITISH JOURNAL OF CANCER (2009)
Proteasome Inhibition Blocks Ligand-Induced Dynamic Processing and Internalization of Epidermal Growth Factor Receptor via Altered Receptor Ubiquitination and Phosphorylation
Aparna H. Kesarwala et al.
CANCER RESEARCH (2009)
A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene
Ji Luo et al.
CELL (2009)
Randomized Phase II Trial of Docetaxel Plus Cetuximab or Docetaxel Plus Bortezomib in Patients With Advanced Non-Small-Cell Lung Cancer and a Performance Status of 2: CALGB 30402
Rogerio Lilenbaum et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells
Callum M. Sloss et al.
CLINICAL CANCER RESEARCH (2008)
Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells
Tina Cascone et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2008)
Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells
Dongwei Zhang et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Bortezomib inhibits cell-cell adhesion and cell migration and enhances epidermal growth factor receptor inhibitor-induced cell death in squamous cell cancer
Jochen H. Lorch et al.
CANCER RESEARCH (2007)
Epidermal growth factor receptor inhibition sensitizes renal cell carcinoma cells to the cytotoxic effects of bortezomib
Jiabin An et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Clinical implications of the mechanism of epidermal growth factor receptor inhibitors
John Marshall
CANCER (2006)
The proteasome: A suitable antineoplastic target
J Adams
NATURE REVIEWS CANCER (2004)
Share Paper
